Tosedostat. Aminopeptidase inhibitor oncolytic

Drugs of the Future

Volumn 34, Issue 2, 2009, Pages 115-118

  Owen, R J ^a   Castaner R ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BB 76163; BORTEZOMIB; CARBOPLATIN; CHR 2797; CYTARABINE; PACLITAXEL; RETINOIC ACID; TOSEDOSTAT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; FATIGUE; FEVER; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; PERIPHERAL EDEMA; RASH; SENSORY NEUROPATHY; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOMITING;

EID: 76649086347     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.02.1339255     Document Type: Article

References (17)

1. Pearson, L.A., Ayscough, A.P., Huxley, P., Drummond, A.H. (British Biotech Pharmaceuticals Ltd.). Cytostatic agents. CA 2323414, EP 1062202, JP 2002506057, WO1999046241.
2. Overall, CM., Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations in the post-trial era. Nat Rev Cancer 2002, 2(9); 657-72.
3. Brown, P.D., Bowden, IJ., Miller, K.M. (British Biotech Pharmaceuticals Ltd.). Use of MMP inhibitors. US 5872152.
4. Krige, D., Needham, L.A., Bowden, LJ. et al CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008, 68(16): 6669-79.
5. Jenkins, C., Mills, K., Pepper, C., Burnett, A. Cellular aminopeptidase inhibition as a target for the therapy of AML by the novel agent CHR-2797. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 1608.
6. Davies, F.E., Moore, H.E., Davenport, E.L. et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Blood [49th Annu Meet Am Soc Hematot (Dec 8-11, Atlanta) 2007] 2007,110(11): Abst 2505.
7. Drummond, A., Callaghan, J., Flores, N., Miles, L., Bawden, L., Farmer, H., Krige, D. Antiproliferative aminopeptidase inhibitors inhibit mTOR and alter expression of Noxa and MIc-1 in leukemic cells via amino acid deprivation. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 4069.
8. Drummond, A.H., Eccles, S.A., Box, G., Hooftman, L.W., Bone, E.A., Needham, L.A. In vivo efficacy of CHR-2797, a novel aminopeptidase inhibitor, in a syngeneic rat HOSP.1 mammary carcinoma model. Proc Am Assoc Cancer Res (AACR) 2005,46: Abst 5850.
9. Hooftman, L.W., Bone, E.A., Drummond, A.H., Needham, L.A., Odedra, R., Wright, A., Laber, D. Effect of the combination of the aminopeptidase inhibitor CHR-2797 and corboplatin on the growth of MDA-MB468 breast carcinoma in nude mice. 17th AACR-NCI-EORTC lnt Conf Mol Targets Cancer (Nov 14-18, Philadelphia) 2005, Abst B188.
10. Hooftman, L.W., Bone, E.A., Drummond, A.H., Needham, L.A., Laber, D.O., Odedra, R., Weight, A. Antiproliferative effect of CHR-2797, a novel aminopeptidase inhibitor in the human breast cancer xenograft, MDA-MB 468. 4th lnt Symp Target Anticancer Ther (March 16-18, Amsterdam) 2006, Abst P.220.
11. Hooftman, L.W., Bone, E.A., Drummond, A.H., Needham, L.A., Laber, D.O., Odedra, R., Wright, A. Antiproliferative effect of CHR-2797, a novel aminopeptidase inhibitor, in the human breast cancer xenograft, MDA-MB 435. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 637.
12. Protheroe, A., Reid, A., Attard, G. et al. A phase I dose finding study of the aminopeptidase inhibitor CHR-2797 in patients with treatment-refractory metastatic cancer. Ann Oncol [31st Eur Soc Med Oncol (ESMO) Congr (Sept 29-Oct 3, Istanbul) 2006] 2006,17(9): Abst 412P.
13. Protheroe, A., Reid, A., Attard, G. et al. First in-human phase I trial of a novel aminopeptidase inhibitor, CHR-2797. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, SuppL): Abst 3537.
14. Davies, F., Ossenkoppele, G., Zachee, P. et al. A phase I study of CHR-2797, an orally active aminopeptidase inhibitor in elderly and/or treatment refractory patients with acute myeloid leukemia or multiple myeloma. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 443.
15. van Herpen, C., Eskens, F., de Jonge, M. et al. A phase 1b dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors. 20th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Oct 21-24, Geneva) 2008, Abst 344.
16. Lowenberg, B., Davies, F., Müller-Tidow, C. et al. A multicenter, phase II study of the aminopeptidase inhibitor, CHR-2797, in the treatment of elderly and/or previously treated patients with acute myeloid leukemia. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 961.
17. Safety and anti-disease activity of oral tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed AML (OPAL) (NCT00780598). ClinicalTrials.gov Web site, February 7,2009.